Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 5, 2007

BioSeek to Ally with UCB for Compound Evaluation

  • BioSeek and UCB will jointly evaluate a number of UCB compounds across several target classes in support of target differentiation, lead development, and drug candidate selection using BioSeek’s BioMAP® Systems.

    BioMAP Systems are a series of human primary cell-based assays designed to replicate cell and pathway interactions in human disease biology. BioMAP profiling provides characterization of drug function including defining mechanism of action and secondary activities and can provide insights into potential clinical applications, according to BioSeek.

    In addition to characterizing previously identified lead compounds, BioSeek is using BioMAP for primary screening to rapidly generate lead compounds that have novel activity in a particular disease setting.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »